For decades, doctors treating fatty liver disease had no approved medicine to offer — only advice about diet, exercise, and watchful waiting. That changed in March 2024, when the FDA approved REZDIFFRA (resmetirom), becoming the first drug ever cleared specifically for nonalcoholic steatohepatitis (NASH), also known by its newer clinical name, MASH (metabolic dysfunction-associated steatohepatitis). Developed by Madrigal Pharmaceuticals, Rezdiffra represents a genuine milestone: a targeted medicine for fatty liver disease that had, until now, gone untreated by any pharmaceutical option.

What Is Rezdiffra and What Does It Treat

Rezdiffra is indicated, alongside diet and exercise, for adults with noncirrhotic NASH who have moderate to advanced liver scarring (fibrosis stages F2–F3). NASH is an advanced form of fatty liver disease in which excess fat causes inflammation and scarring in the liver — left unaddressed, it can progress toward cirrhosis. As a liver medication for fatty liver, Rezdiffra doesn't just manage symptoms; clinical trials showed it could improve liver fibrosis and resolve steatohepatitis in a meaningful share of patients, which is why its approval was such a turning point for hepatology.

How Rezdiffra Works

Rezdiffra is a thyroid hormone receptor-beta (THR-beta) agonist. It works by targeting a receptor in the liver that helps regulate fat metabolism, helping the liver break down accumulated fat, reduce inflammation, and slow the buildup of scar tissue. This mechanism is specific to a subtype of thyroid receptor found mainly in the liver, which is part of why it can act on liver fat without the broader hormonal effects of older thyroid-based approaches.

Rezdiffra's Approval and Launch

Rezdiffra's accelerated approval was based on improvements in liver histology observed in Phase 3 trials, with continued approval contingent on confirmatory trial data. Since its 2024 launch, it has been distributed primarily through a specialty pharmacy network rather than retail pharmacies — standard for high-cost specialty biologics and small-molecule drugs that require closer patient monitoring, including periodic liver enzyme checks.

Cost, Insurance, and Copay Support

Rezdiffra's list price is substantial — roughly $47,400 per year — so financial assistance is a central part of how patients actually access it. Madrigal offers a few main paths:

• Rezdiffra Copay Savings Card: Eligible, commercially insured patients may pay as little as $0 per month, subject to eligibility rules and program terms (details at copay.rezdiffra.com). This copay program is not valid for patients on Medicare, Medicaid, or other federal/state health programs.

• Madrigal Patient Support: A broader assistance hub offering help navigating insurance, prior authorizations, nurse navigators for treatment support, and guidance toward other financial assistance options — including for Medicare patients who can't use the copay card.

• Third-party discount programs (e.g., GoodRx-style coupons) can also lower cash prices, though they typically save less than the manufacturer's own copay program for insured patients.

Patients should always confirm current terms directly through Madrigal's official channels, since copay program rules and pricing can change.

Considerations Before Starting Treatment

Rezdiffra isn't right for everyone. Prescribing information notes a risk of liver-related side effects (hepatotoxicity), so liver function is monitored during treatment. Gallbladder-related events (like gallstones) have also been reported more often than with placebo, and Rezdiffra can interact with certain statins, potentially raising their levels in the blood. Anyone considering it should have a full discussion with a liver specialist about their health history, other medications, and monitoring needs.

Looking Ahead

Because NASH/MASH previously had no approved pharmacologic treatment, Rezdiffra's arrival has reshaped the treatment landscape and spurred interest in other drugs for fatty liver disease now in development. For now, though, it remains a first-in-class option — and for patients newly diagnosed with NASH, staying informed about eligibility, cost-assistance programs, and ongoing research is one of the most useful things they can do while working with their doctor on a treatment plan.

Latest Reports Offered by Delveinsight

ibi363 mechanism of action, jak kinase inhibitor alopecia, dupixent copd, janus kinase inhibitors, fibroblast growth factors, lysosomal storage disorder, sleep technologies, lysosomal storage disorders, neiman pick, lysosomal storage disorder, bispecific antibody news, the lepr, dawnzera, egfr inhibitors, ai diagnostics, nanorobotics, hutchinson gilford progeria disease, immunohistochemistry, asmd, parenteral feeding , sodium channel antagonist, phosphodiesterase 4, ai pathology news, medications for uc, amyotrophic lateral sclerosis market, complement inhibitors, point-of-care diagnostics news, digital therapeutics, what is alternative medicine, definition of health disparity, b7-h3, digital therapeutics news, amyotrophic lateral sclerosis market, pecoma cancer, digital pathology news today, sglt2 inhibitor list, hgps disease, what are nanobots, alternative medicine is an alternative to what, human papillomavirus 16

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com